Navigation Links
'If Hamlet give the first or second hit': The development of Burkitt's lymphoma
Date:11/8/2011

The human c-myc gene encodes a transcription factor (MYC) involved in the regulation of a vast number of other genes it has been estimated that the transcription of about one in six genes is somehow under the control of MYC. Perhaps because of MYC's wide range of targets, mutations of the c-myc gene are frequently associated with a variety of tumours, not only with Burkitt's lymphoma. Mutations that lead to excessive amounts of the MYC protein are particularly threatening.

It has long been known that Burkitt's lymphoma only develops when MYC is mutated or overexpressed, although experiments in mice have shown that some animals live quite happily and healthily with higher levels of the MYC protein. This observation is consistent with the "second hit" model for the origin of cancer: as well as a change to c-myc, a second gene must also be disturbed before disease is initiated. In the case of lymphomas, the second hit is often in the p53 or the Bcl2 gene. Loss of p53 or increased amounts of the BCL2 protein are both associated with lymphoma. But how does the course of the disease relate to the nature of the second hit?

This question has now been investigated by Sexl's and Stoiber's groups. Using a mouse model of human lymphoma, the scientists compared the effects on the immune system of deleting the p53 gene or over-activating the Bcl2 gene, or both. The results were dramatic. If the p53 gene was mutated, the resulting tumours were no longer recognized and killed by the mouse's immune system. In other words, such tumours escaped the mouse's normal "surveillance" mechanism and went on to cause full-blown lymphoma. On the other hand, if instead the Bcl2 gene was overexpressed (to produce more BCL2 protein), the mouse's immune system could recognize and attack the tumour cells, thereby slowing or preventing cancer development. If both the p53 and the Bcl2 genes were affected, immune recognition remained efficient, in other words the Bc
'/>"/>

Contact: Prof Veronika Sexl
veronika.sexl@vetmeduni.ac.at
43-125-077-2910
University of Veterinary Medicine -- Vienna
Source:Eurekalert

Page: 1 2

Related medicine news :

1. UGA researchers develop first mouse model to study important aspect of Alzheimer’s
2. New study from NYUCN is the first to look at nursing error disclosure in nursing homes
3. Cardiovascular magnetic resonance now an important first-line test
4. UK HealthCare surgeons are first to perform novel procedures prior to transplant
5. First-of-its-kind study creates new tool for targeted cancer drug development
6. Clinical trial shows first evidence that anal cancer is preventable
7. Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo
8. Veterinary researchers discover first US strains of hepatitis E virus from rabbits
9. First report of increased safety using simultaneous techniques for cardiac testing published
10. UGA scientists team up to define first-ever sequence of biologically important carbohydrate
11. New national research center for bowel disease in London will be a UK first
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... new study in the Annals,of Internal Medicine adds ... patients for the bacterium MRSA (methicillin-resistant,Staphylococcus aureus) is ... The study, published yesterday, resulted in a 70%,reduction ... in the,Evanston Northwestern Healthcare System, located near Chicago., ...
... 2008, WASHINGTON, March 18 Following is the,National ... The Bulletin, which is free of charge and available ... the latest issues and news,affecting people with disabilities. To ... click on Online mailing list archives,select NCD-NEWS-L, click on ...
... One of the nations oldest and most respected non-profit ... fellowships to underrepresented minority students and scientists to attend ... 5-9. The American Physiological Society (APS), which administers the ... travel awards. , APS administers the program with financial ...
... and SHANGHAI, China, March 18 ,Flagship Global Health, ... Limited (CHC), listed on the Stock Exchange of ... a strategic alliance to,jointly utilize their resources and ... leading insurance companies, including,China Ping An and China ...
... safety tests and is relatively painless , , TUESDAY, March 18 ... veins proved safe in patients, according to the results of ... found that use of injectable Varisolve microfoam didn,t cause any ... patients with a common heart defect. , Since 1997, ...
... HILL, N.C., March 18 The Internet has ... leaders,haven,t lost sight of the value of an ... a relationship and high performing sales,groups -- irrespective ... of their time identifying and addressing existing clients, ...
Cached Medicine News:Health News:Evanston-Northwestern Study Proves Effectiveness of MRSA Screening to Reduce Hospital Infections 2Health News:National Council on Disability Monthly Bulletin for February, 2008 2Health News:National Council on Disability Monthly Bulletin for February, 2008 3Health News:National Council on Disability Monthly Bulletin for February, 2008 4Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 2Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 3Health News:Flagship Global Health and China HealthCare Holdings Form Strategic Alliance 2Health News:Flagship Global Health and China HealthCare Holdings Form Strategic Alliance 3Health News:New Foam Treatment for Varicose Veins 2Health News:High Performing Sales Forces Follow Same Path to Excellence 2
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... YORK, May 24, 2011 Reportlinker.com ... report is available in its catalogue: ... (RVO) Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0511065/Retinal-Vein-Occlusion-RVO-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ...
... May 24, 2011 Reportlinker.com announces that ... in its catalogue: Triple ... http://www.reportlinker.com/p0284984/Triple-Analysis-Lung-Cancer-Lymphoma-and-Angiogenesis.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... drug development strategies in both Lung Cancer ...
Cached Medicine Technology:Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 2Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 3Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 4Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis 5
... founded in 1975, is a full-service, ... clients throughout the United States and ... focuses on cutting-edge research and development ... refinement of existing diagnostic tests to ...
... ActCel Hemostatic Gauze is a collagen-like ... It is an effective, patented, hemostatic agent ... bleeding from open wounds and in body ... thrombin or collagen and is hypoallergenic. When ...
Sharp tipped straight scissors. For cutting in the iris plane or cutting peripheral membranes. May also be useful in ROP cases....
Sharp tipped illuminated scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and...
Medicine Products: